AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27592690
Drug: Continuous adductor
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous adductor canal block (ACB) with 0.5% ropivacaine infusing at 2.5 ml/h
Trial: 25268806
Drug: β-glucan 1000
RxNorm normalized name: Beta glucan
DrugBank: Yeast beta-D-glucan (DB19271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-glucan 1000 mg once daily for 7 days
Trial: 22175661
Drug: Four-cluster solution
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-cluster solution
Trial: 19858250
Drug: Azithromycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (2 g doses given 24 h apart)
Trial: 19858250
Drug: Sulfadoxine-pyrimethamine (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine (1,500 mg or 75 mg) or chloroquine (450 mg base daily for 3 days)
Trial: 17991116
Drug: Intravaginal slingplasty
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal slingplasty (IVS) treatment
Trial: 16390772
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg of daily genistein
Trial: 12170527
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist therapy for endometriosis
Trial: 11237197
Drug: DHA-rich oil
RxNorm normalized name: Ulkenia DHA oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich oil capsules containing 1.5-1.8 g DHA/d
Trial: 11237197
Drug: Control oil
RxNorm normalized name: SALICYLIC ACID 29.2 mg TOPICAL LIQUID [Acne Control oil-free Cleansing]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control oil capsules containing 97% soybean oil plus 3% fish oil
Trial: 1509912
Drug: Mannitol solution
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol solution at 400 mOsm/kg (Group 1)
Trial: 1509912
Drug: Mannitol solution
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol solution plus allopurinol (Group 2)
Trial: 6233188
Drug: Motretinide 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motretinide 0.1% vanishing cream
Trial: 31351241
Drug: Parent-Child Interaction
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-Child Interaction Therapy-informed behavioral treatment
Trial: 23845200
Drug: TrP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TrP therapy (manual pressure applied to taut bands and passive stretching)
Trial: 23845200
Drug: Simulated TrP
RxNorm normalized name: Trp
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated TrP therapy (no additional pressure, longitudinal stroking but no additional stretching)
Trial: 23845200
Drug: TrP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TrP therapy
Trial: 23845200
Drug: Simulated TrP
RxNorm normalized name: Trp
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated TrP therapy
Trial: 21933376
Drug: Intermittent screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent screening and treatment (IST) of malaria
Trial: 16403592
Drug: Fructose supplementation
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose supplementation (7.5 g) tri‐daily after each main meal
Trial: 16403592
Drug: Maltodextrin supplementation
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin supplementation (7.5 g) tri‐daily after each main meal
Trial: 8242506
Drug: MMR vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccine administered at 13 months
Trial: 8242506
Drug: MMR vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccine administered at 15 months
Trial: 8242506
Drug: MMR vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccine (both groups)
Trial: 23363776
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one capsule per day for 4 months)
Trial: 20829329
Drug: T/FAC (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T/FAC (weekly paclitaxel × 12 followed by FAC × 4)
Trial: 11220522
Drug: Sibutramine 15
RxNorm normalized name: sibutramine 15 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 15 mg once daily
Trial: 8695089
Drug: Pressure support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure support (PS) titrated to produce a tidal volume (VT) of 8 ml/kg body weight
Trial: 7949749
Drug: Cyclic oestrogen/progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic oestrogen/progestogen therapy (group 1, n = 20)
Trial: 7949749
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral calcium dose of 2 g (group 2, n = 17)
Trial: 7949749
Drug: Intermittent cyclic
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent cyclic etidronate therapy (group 3, n = 19)
Trial: 7949749
Drug: ADFR treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADFR treatment with triiodothyronine and etidronate (group 4, n = 18)
Trial: 3358644
Drug: Alprazolam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (mean daily dose 5.7 mg)
Trial: 3358644
Drug: Placebo (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (mean daily dose 7.5 capsules)
Trial: 30390894
Drug: Individualized nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized nutritional support (126 kJ/kg and 1.5-2.0 g protein/kg) during hospitalization
Trial: 21124326
Drug: Olmesartan plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan plus a calcium channel blocker (CCB)
Trial: 21124326
Drug: Olmesartan plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan plus a thiazide diuretic
Trial: 15310999
Drug: Immediate endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate endocrine treatment (luteinizing hormone‐releasing hormone agonist and 1 month of antiandrogen treatment or surgical castration)
Trial: 15310999
Drug: Delayed endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed endocrine treatment
Trial: 8534760
Drug: Aerosol amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosol amphotericin B inhalations (10 mg twice daily)
Trial: 2143046
Drug: Verapamil 120
RxNorm normalized name: verapamil 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 120 mg two or three times daily for 3 months
Trial: 31232992
Drug: Extraoral approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraoral approach for BTX‐A injection into the lateral pterygoid muscle (20 IU BTX‐A)
Trial: 31232992
Drug: Intraoral approach
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRADURAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoral approach for BTX‐A injection into the lateral pterygoid muscle (20 IU BTX‐A)
Trial: 28363363
Drug: Dexamethasone (DXM)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DXM) 0.25 mg/kg/dose every 6 hours for 48 hours
Trial: 23972540
Drug: Healing Touch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healing Touch (HT) and Body Talk Cortices (BTC) for 6 months, with weekly HT sessions and daily BTC technique.
Trial: 2187585
Drug: Cyproheptadine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproheptadine (8 mg orally three times a day)
Trial: 7033008
Drug: Des-phe insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Des-phe insulin (regular and semilinte preparations)
Trial: 7033008
Drug: Des-phe insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Des-phe insulin
Trial: 7033008
Drug: Unmodified insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unmodified insulin
Trial: 27519620
Drug: High-dose level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose level SA3Ag
Trial: 17685844
Drug: ACIDFORM gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACIDFORM gel with a diaphragm
Trial: 16015060
Drug: Endovascular therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapies including protection and thromboaspiration devices, new atherectomy devices, and cryoplasty.
Trial: 7783062
Drug: Zileuton 600
RxNorm normalized name: zileuton 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton 600 mg qid
Trial: 2515524
Drug: Altretamine preparation
RxNorm normalized name: Altretamine
DrugBank: Altretamine (DB00488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Altretamine preparation 1
Trial: 2515524
Drug: Altretamine preparation
RxNorm normalized name: Altretamine
DrugBank: Altretamine (DB00488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Altretamine preparation 2
Trial: 2515524
Drug: Altretamine preparation
RxNorm normalized name: Altretamine
DrugBank: Altretamine (DB00488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Altretamine preparation 3 (control)
Trial: 7253868
Drug: Post-blood trial
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-blood trial after 920 ml equivalent of whole blood
Trial: 31811339
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) gel dressing
Trial: 28658251
Drug: Oral drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drug detected
Trial: 28658251
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral drug detected
Trial: 25296623
Drug: Varenicline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline plus nicotine patch (21 mg every 24 hours)
Trial: 20433806
Drug: Intradermal hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal hepatitis B vaccination after topical application of imiquimod (250 mg)
Trial: 20433806
Drug: Intradermal hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal hepatitis B vaccination without imiquimod application (control group)
Trial: 18760149
Drug: Intravenous BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous BCAA supplementation (n=22; 19.6g/d)
Trial: 11910268
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ziprasidone
Trial: 23307953
Drug: Oxygen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen treatment
Trial: 2117190
Drug: No oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oxygen treatment
Trial: 6679234
Drug: Terazosin hydrochloride
RxNorm normalized name: Terazosin Hydrochloride
DrugBank: Terazosin (DB01162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terazosin hydrochloride (long-term therapy)
Trial: 6679234
Drug: Terazosin hydrochloride
RxNorm normalized name: Terazosin Hydrochloride
DrugBank: Terazosin (DB01162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terazosin hydrochloride (short-term therapy)
Trial: 31150095
Drug: LB 133
RxNorm normalized name: spinosad
DrugBank: Spinosad (DB08823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LB 133 mg
Trial: 25127173
Drug: LY2951742 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2951742 (150 mg) subcutaneous injection every 2 weeks for 12 weeks
Trial: 25127173
Drug: Placebo subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injection every 2 weeks for 12 weeks
Trial: 19203562
Drug: CET +
RxNorm normalized name: CET
DrugBank: Cefalotin (DB00456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CET + PSE (10 mg cetirizine and 120 mg pseudoephedrine)
Trial: 19203562
Drug: CET (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CET (single treatment)
Trial: 19203562
Drug: PSE (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSE (single treatment)
Trial: 17680909
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) + pharmacotherapy
Trial: 15169696
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg/day, with option to increase to 40 mg/day at week 4)
Trial: 11433064
Drug: 30 microgram
RxNorm normalized name: Levonorgestrel 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microgram of LD vaccine
Trial: 9757887
Drug: Vasoactive intestinal
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive intestinal polypeptide (VIP) 4 pmol x kg(‐1) x min(‐1) in 50 mL of normal saline infused i.v. for 60 minutes plus oxytocin (2 IU injected plus 0.07 IU/min infused for 60 minutes)
Trial: 9757887
Drug: Vasoactive intestinal
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive intestinal polypeptide (VIP) 4 pmol x kg(‐1) x min(‐1) in 50 mL of normal saline infused i.v. for 60 minutes
Trial: 3287685
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment with vincristine, prednisone, L‐asparaginase and rubidomycin (Group B)
Trial: 3287685
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment with vincristine, prednisone and L‐asparaginase (Group A)
Trial: 8764356
Drug: Niravoline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niravoline (2 mg dose, single 30-min i.v. infusion)
Trial: 30497695
Drug: Oral carbohydrate
RxNorm normalized name: omega-3 carboxylic acids Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral carbohydrate loading (400 mL, 2 hours before surgery)
Trial: 22730955
Drug: Optimized treatment-as-usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized treatment-as-usual (O-TAU)
Trial: 17556623
Drug: Parenteral aminosidine
RxNorm normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral aminosidine sulphate (AS) 14 mg/kg/d for 21 days
Trial: 17556623
Drug: Intravenous meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous meglumine antimonate (MA) 20 mg/kg/d for 28 days
Trial: 12939546
Drug: Rate control
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rate control combined with antithrombotic therapy
Trial: 12939546
Drug: Rhythm control
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm control combined with antithrombotic therapy
Trial: 12939546
Drug: Efficacy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efficacy and safety of drugs used in treating AF
Trial: 10730228
Drug: 36 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 Gy radiation treatment
Trial: 10730228
Drug: 10 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 Gy radiation treatment
Trial: 10730228
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no radiation treatment)
Trial: 8931411
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa therapy (10 million U three times a week for 16 weeks)
Trial: 2071783
Drug: 10 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 months of immunotherapy (IT) at 2 micrograms of Amb a I
Trial: 2071783
Drug: 22 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 months of immunotherapy (IT) at 24 micrograms of Amb a I
Trial: 2071783
Drug: 1 year
RxNorm normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 year of immunotherapy (IT) at 2 micrograms of Amb a I
Trial: 2071783
Drug: 2 years
RxNorm normalized name: Childrens Panadol 5 - 12 Years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 years of immunotherapy (IT) at 2 micrograms of Amb a I
Trial: 2071783
Drug: 3 years
RxNorm normalized name: NanoVM 1-3 years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 years of immunotherapy (IT) at 24 micrograms of Amb a I
Trial: 6129719
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 to 320 mg per day for 6 to 31 months)
Trial: 26363342
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of autologous, unfractionated bone marrow
Trial: 26467901
Drug: Placebo intervention:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intervention: infusion of autologous blood
Trial: 20041782
Drug: Yeast hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast hydrolysate (YH) administered for 2 weeks
Trial: 18605225
Drug: COLD-fX (immune-modulator)
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COLD-fX (immune-modulator)
Trial: 18605225
Drug: REMEMBER-fX (neuro-modulator)
RxNorm normalized name: Prevail-FX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REMEMBER-fX (neuro-modulator)
Trial: 15234398
Drug: HDB tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDB tirofiban (25 microg/kg/3 min, and infusion of 0.15 microg/kg/min for 24 to 48 h)
Trial: 8378292
Drug: DA Salbutamol/DNCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA Salbutamol/DNCG (0.1 mg Salbutamol and 1.0 mg DNCG/puff)
Trial: 8378292
Drug: DA Salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DA Salbutamol alone (0.1 mg Salbutamol puff)
Trial: 3527070
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide and droperidol (regimen I)
Trial: 3527070
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high-dose metoclopramide, droperidol and methylprednisolone (regimen II)
Trial: 31470006
Drug: Small-intestinal-release peppermint
RxNorm normalized name: pork intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-intestinal-release peppermint oil (182 mg)
Trial: 31470006
Drug: Ileocolonic-release peppermint
RxNorm normalized name: Peppermint
DrugBank: Peppermint (DB10984)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ileocolonic-release peppermint oil (182 mg)
Trial: 20516031
Drug: DMARD monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMARD monotherapy
Trial: 18982929
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg simvastatin per day
Trial: 16092581
Drug: Sustained-release bupropion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release bupropion, 300 mg/d
Trial: 12585148
Drug: Danxiaoling Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danxiaoling Pill (DXLP)
Trial: 11869855
Drug: Intracoronary estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary estrogen administration
Trial: 7924241
Drug: Individual Treatment
RxNorm normalized name: Alex Rubber Tip Individual Pack 3/4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Treatment (IT)
Trial: 7924241
Drug: Individual Treatment
RxNorm normalized name: Alex Rubber Tip Individual Pack 3/4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Treatment (Rehearsal IT)
Trial: 2573963
Drug: Antacids and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids and cholinolytics
Trial: 4840431
Drug: Buffered cephalothin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered cephalothin solution
Trial: 4840431
Drug: Unbuffered cephalothin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unbuffered cephalothin solution
Trial: 31167050
Drug: Azithromycin (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (twice yearly for 2 years, followed by additional distributions in MORDOR II)
Trial: 22068177
Drug: P6: home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P6: home use chlorine solution (Q'boa® at 0.45% for 10 min)